Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

Canadian Intellectual Property Office
An agency of Industry Canada

CA 2594893 C 2014/05/13

(11)(21) 2 594 893

(12) BREVET CANADIEN
CANADIAN PATENT

(13) C

(86) Date de dépôt PCT/PCT Filing Date: 2006/01/13
(87) Date publication PCT/PCT Publication Date: 2006/07/20
(45) Date de délivrance/Issue Date: 2014/05/13
(85) Entrée phase nationale/National Entry: 2007/07/13
(86) N° demande PCT/PCT Application No.: GB 2006/000114
(87) N° publication PCT/PCT Publication No.: 2006/075166
(30) Priorité/Priority: 2005/01/14 (GB0500702.6)

(51) Cl.Int./Int.Cl. *C07F 17/02* (2006.01), *C07B 31/00* (2006.01), *C07B 53/00* (2006.01)

(72) Inventeurs/Inventors:
MCCORMACK, PETER, GB;
CHEN, WEIPING, GB;
WHITALL, JOHN, GB

(73) Propriétaire/Owner:
SOLVIAS AG, CH

(74) Agent: PARLEE MCLAWS LLP

(54) Titre : PHOSPHINES CHIRALES DE PHOSPHORE A BASE DE METALLOCENE
(54) Title: METALLOCENE-BASED CHIRAL PHOSPHINES AND ARSINES



(I)



(II)

(57) Abrégé/Abstract:
The present invention concerns a metallocene-based phosphine ligand for use in enantioselective catalysis, the ligand having the Formula (I): Wherein M is a metal; Z is P or As; L is a suitable linker; R^1 is selected from alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkoxy, cycloalkylamino carbocyclic aryl, substituted and unsubstituted carbocyclic aryloxy, heteroaryl, heteroaryloxy, carbocyclic arylamino and heteroarylamino; X* is selected from (II): Wherein R, R^2 and R^3 are independently selected from optionally substituted branched- and straight-chain alkyl, cycloalkyl, heterocycloalkyl, carbocyclic aryl, and heteroaryl.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 July 2006 (20.07.2006)

PCT

(10) International Publication Number
WO 2006/075166 A1

(51) International Patent Classification:
C07F 17/02 (2006.01) *C07B 31/00* (2006.01)
C07B 53/00 (2006.01)

(21) International Application Number:
PCT/GB2006/000114

(22) International Filing Date: 13 January 2006 (13.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0500702.6 14 January 2005 (14.01.2005) GB

(71) Applicant *(for all designated States except US)*: **PHOENIX CHEMICALS LTD.** [GB/GB]; 34 Thursby Road, Croft Business Park, Bromborough, Wirral, Merseyside CH62 3PW (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MCCORMACK, Peter** [IE/GB]; Phoenix Chemicals Ltd., 34 Thursby Road, Croft Business Park, Bromborough, Wirral, Merseyside CH62 3PW (GB). **CHEN, Weiping** [CN/GB]; 26 Baldwin Avenue, Liverpool L16 3GD (GB). **WHITTALL, John** [GB/GB]; 23 Sunningdale Avenue, Hestbank, Lancaster, LA2 6DF (GB).

(74) Agent: **BRAND, Thomas, Louis**; W.P. THOMPSON & CO., 55 Drury Lane, London WC2B 5SQ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES



(I)



(II)

(57) Abstract: The present invention concerns a metallocene-based phosphine ligand for use in enantioselective catalysis, the ligand having the Formula (I): Wherein M is a metal; Z is P or As; L is a suitable linker; R^1 is selected from alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkoxy, cycloalkylamino carbocyclic aryl, substituted and unsubstituted carbocyclic aryloxy, heteroaryl, heteroaryloxy, carbocyclic arylamino and heteroarylamino; X* is selected from (II): Wherein R, R^2 and R^3 are independently selected from optionally substituted branched- and straight-chain alkyl, cycloalkyl, heterocycloalkyl, carbocyclic aryl, and heteroaryl.

WO 2006/075166 A1

METALLOCENE-BASED CHIRAL PHOSPHINES AND ARSINES

This invention relates to novel chiral metallocene-based phosphine ligands and methods for their preparation. In addition, this invention relates to metal-ligand complexes that can be used as catalysts or precatalysts for asymmetric transformation reactions to generate products of high enantiomeric excess. Similarly structured arsines are also within the scope of this invention.

Certain known diphosphine ligands exhibit chirality only at the phosphorus atoms:



FerroTane



4a: R = o-anisyl
4b: R = 1-naphthyl



5



f-binaphane



6

The synthesis of chiral 1,1'-bis(phosphetano) ferrocenes (FerroTANE) has been independently reported by Marinetti[15] and Burk[16]. FerroTANE has been

successfully applied in Rh-catalyzed hydrogenation of itaconates and (E)-β-(acylamino) acrylates[17].

Mezzetti[18] and van Leeuwen[19] have independently reported P-chiral ferrocenyl bisphosphines 4a and 4b. These two ligands have shown excellent enantioselectivities (up to 99% ee) for asymmetric hydrogenation of α-dehydroamino acid derivatives.

Zhang has reported a 1,1'-bis(Phospholanyl) ferrocene ligand 5 with ketal substitutes at the 3 and 4 positions. [20] The ligand has shown excellent enantioselectivities in hydrogenation of β-dehydroamino acid derivatives. The ketal groups of the ligand are important for achieving the high enantioselectivity, since the corresponding ligand without ketal groups only provides moderate ee's. Zhang has also developed a 1,1'-bis(dinaphthophosphepinyl) ferrocene ligand, f-binaphane, which has been successfully applied in the Ir-catalyzed hydrogenation of acyclic aryl imines. [21]

Reetz has developed a binaphthol-derived ferrocene-based bisphosphonite ligand 6[22], which has shown excellent reactivities and enantioselectivities in Rh-catalyzed hydrogenation of itaconates and α-dehydroamino acid derivatives.

Another class of known ligands exhibits both planar and phosphorus chirality:



7a: R = 1-naphthyl
7b: R = 2-biphenylyl

Van Leeuwen has reported ferrocene-based bisphosphines combining planar and phosphorus chirality 7a and 7b[23]. These two ligands have shown excellent enantioselectivities (up to 99% ee) for asymmetric allylic alkylations.

More recently, Togni reported the first tridentate ferrocene-based phosphine ligand 12 combining planar, phosphorus and carbon chirality. [24]



$(R)_C$-$(S)_{Fe}$-$(S)_P$-12



$(R)_C$-$(S)_{Fe}$-$(R)_P$-12

We have previously reported novel classes of chiral phosphine and arsine ligands, and processes for their preparation, and these are reported in co-pending applications published under WO-A-2005/068477 and WO-A-2005/068478.

Oohara et al discloses (Tetrahedron: Asymmetry 14 (2003) 2171-2175) (S,S)-1,2-bis[(ferrocenyl)methylophosphino]ethane prepared via phosphine-borane intermediates, and the use of this ligand in the rhodium-catalyzed asymmetric hydrogenation of dehydroamino acid derivatives, and in the palladium-catalyzed asymmetric allylic alkylation of 1,3-diphenyl-2-propenyl acetate.

It would be advantageous to design improved chiral bisphosphine ligands for use in enantioselective catalysis.

According to the present invention there is provided a metallocene-based phosphine or arsine ligand for use in enantioselective catalysis, the ligand having the Formula:



Wherein:

M is a metal;

Z is P or Ar;

L is a suitable linker;

R^1 is selected from substituted and unsubstituted, branched- and straight-chain alkyl, alkoxy, alkylamino, substituted and unsubstituted cycloalkyl, substituted and unsubstituted cycloalkoxy, substituted and unsubstituted cycloalkylamino, substituted and unsubstituted carbocyclic aryl, substituted and unsubstituted carbocyclic aryloxy, substituted and unsubstituted heteroaryl, substituted and unsubstituted heteroaryloxy, substituted and unsubstituted carbocyclic arylamino and substituted and unsubstituted heteroarylamino, wherein the or each heteroatom is independently selected from sulphur, nitrogen, and oxygen;

and

X* is selected from:



Wherein R, R^2 and R^3 are independently selected from substituted and unsubstituted, branched- and straight-chain alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted carbocyclic aryl, and substituted and unsubstituted heteroaryl wherein the or each heteroatom is independently selected from sulphur, nitrogen, and oxygen.

The R^2 and R^3 groups may be substituted by each other, forming together an optionally substituted hetero-ring system.

Preferably M is Fe, although Ru may be another preferred M.

L preferably comprises a difunctional moiety having the capability at each functionality to bind to phosphorus or arsenic, as the case may be. Generally the linker (L) will be derived from a difunctional compound, in particular a compound having at least two functional groups capable of binding to phosphorus or arsenic, as the case may be. The difunctional compound may

conveniently comprise a compound which can be di-lithiated or reacted to form a di-Grignard reagent, or otherwise treated, to form a dianionic reactive species which can then be combined directly with phosphorus or arsenic, in a diastereoselective manner to form a chiral phosphorus or arsenic as the case may be. In this case, a first anionic component of the dianionic reactive species may combine with a phosphorus (or arsenic) substituent in a first ligand precursor of the ligand according to the invention, and a second anionic component of the dianionic reactive species may combine again in a diastereoselective manner with a phosphorus (or arsenic) substituent in a second ligand precursor of the ligand again to form a chiral phosphorus (or arsenic) centre according to the invention (the first and second ligand precursors being the same as each other) to connect the first and second ligand precursors together via the linker. Usually a leaving group such as a halide will be provided on the phosphorus (or arsenic) substituents of the first and second ligand precursors, which leaving group departs on combination of the anionic component with the phosphorus (or arsenic) substituent. The following scheme is illustrative of this process:



For example, L may be selected from ferrocene and other metallocenes, diphenyl ethers, xanthenes, 2,3-benzothiophene, 1,2-benzene, succinimides, cyclic anhydides and many others. Conveniently, although not necessarily such dianionic linkers may be made from a corresponding di-halo precursor, eg:



di-lithio diphenyl ether

Wherein R' represents any suitable number of any one or more suitable substituents.

Other suitable dianionic linkers may be represented as follows:



However, ferrocene and other metallocenes may also be selected for use as linkers in accordance with the invention, and there are many other suitable moieties which could also be selected.

Preferred R^1 include phenyl, methyl, cyclohexyl and t-butyl groups.

Preferred R^2 and R^3 include, independently, methyl, ethyl, isopropyl and t-butyl groups. Also, R^2 and R^3 may form, together with the nitrogen to which they are attached, an optionally substituted hetero-ring such as morpholine, pyrollidine, piperidine, and derivatives thereof.

Certain ligands of the invention are derived from Ugi's amine and one preferred ligand in accordance with the invention (wherein the dianionic linker is ferrocene) may be represented as follows:



The same preferred ligand, with the Ugi amine groups fully represented may be shown as :



The invention also relates to the enantiomers and diastereomers of the ligands described above.

Ligands in accordance with the invention may also be represented as follows:



Wherein M, L, R^1 and X* are as previously defined, and wherein the phosphorus may if desired be at least partially replaced by arsenic.

The ligand of the invention exhibits chirality at phosphorus (or arsenic). Preferably, the chiral configuration of the phosphorus (or arsenic) substituents at opposite ends of the linker molecule is the same.

Also provided in accordance with the invention is a transition metal complex comprising a transition metal coordinated to the ligand of the invention. The metal is preferably a Group VIb or a Group VIII metal, especially rhodium, ruthenium, iridium, palladium, platinum or nickel.

Synthesis of ferrocene-based phosphorus chiral phosphines in accordance with the invention may be effected in accordance with the following scheme:



wherein L is a linker derived from an organolithium species or Grignard reagent $L(G)_2$ and wherein X* and R^1 are as previously defined. The same synthetic scheme is generally applicable to other chiral metallocene-based ligands in accordance with the invention.

The invention will now be more particularly illustrated with reference to the following Examples.

Example 1



L1

***1,1' bis-[(S_P,R_C,S_{Fe})(1-N,N-Dimethylamino)ethylferrocenyl)phenylphosphino] ferrocene* L1**

To a solution of (R)-N,N-dimethyl-1-ferrocenylethylamine [(R)-Ugi's amine] (3.09 g, 12 mmol) in Et_2O (20 ml) was added 1.5 M t-BuLi solution in pentane (8.0 ml, 12.0 mmol) at –78 °C. After addition was completed, the mixture was warmed to room temperature, and stirred for 1.5 h at room temperature. The mixture was then cooled to –78 °C again, and dichlorophenylphosphine (1.63 ml, 12.0 mmol) was added in one portion. After stirring for 20 min at –78 °C, the mixture was

slowly warmed to room temperature, and stirred for 1.5 h at room temperature. The mixture was then cooled to –78 °C again, and a suspension of 1,1' dilithioferrocene [prepared from 1,1' dibromoferrocene (1.72 g, 5.0 mmol) and 1.5 M t-BuLi solution in pentane (14.0 ml, 21.0 mmol) in Et_2O (20 ml) at –78 °C] was added slowly via a cannula. The mixture was warmed to room temperature and allowed to stir for 12 h. The reaction was quenched by the addition of saturated $NaHCO_3$ solution (20 ml). The organic layer was separated and dried over $MgSO_4$ and the solvent removed under reduced pressure. The filtrate was concentrated. The residue was purified by chromatography (SiO_2, hexane-EtOAc-Et_3N = 85:10:5) to afford an orange solid (3.88 g, 85%) as a mixture of 95% *bis*-(S_P,R_C,S_{Fe}) title compound **L1** and 5% (R_P,R_C,S_{Fe}-S_P,R_C,S_{Fe}) *meso* compound. The *meso* compound can be removed by further careful purification using chromatography (SiO_2, hexane-EtOAc-Et_3N = 85:10:5). Orange/yellow crystalline solid m.p. 190-192 °C. $[\alpha]_D$ = -427 ° (c=0.005 (g/ml), toluene); ^1H NMR ($CDCl_3$, 400.13 MHz): δ 1.14 (d, 6H,J = 6.7 Hz), 1.50 (s, 12H); 3.43 (m, 2H); 3.83 (m, 2H); 3.87 (m, 2H); 4.01 (s, 10H), 4.09 (t, 2H, J = 2.4 Hz); 4.11 (m, 2H); 4.20 (m, 2H); 4.28 (m, 2H); 4.61 (m, 2H); 4.42 (d, 2H, J = 5.3 Hz); 7.18 (m, 6H); 7.42(m, 4H) ppm. ^{13}C NMR ($CDCl_3$, 100.61 MHz): δ 38.28, 57.40 (d, J = 5.6 Hz); 67.02, 69.04 (d, J = 4.0 Hz); 69.16 (d, J = 51.6 Hz); 69.66, 71.60 (d, J = 4.8 Hz), 71.91 (d, J = 7.2 Hz), 72.18 (d, J = 5.6 Hz), 75.96 (d, J = 35.7 Hz), 79.96 (d, J = 6.4 Hz), 95.73 (d, J = 19.1 Hz), 127.32 (d, J = 7.9 Hz), 127.62, 133.12 (d, J = 21.4 Hz), 139.73 (d, J = 4.0 Hz). ^{31}P NMR ($CDCl_3$, 162 MHz): δ –34.88 (s). Found: C, 65.53; H, 5.92; N 3.01 Calculated for $C_{50}H_{54}Fe_3N_2P_2$; C,

65.81; H, 5.97; N, 3.07. HRMS (10eV, ES+): Calcd for $C_{50}H_{55}Fe_3N_2P_2$ $[M+H]^+$: 913.1889; Found: 913.1952.

The label S_P refers to S configuration at phosphorus, R_C refers to R configuration at carbon (or other auxiliary) and S_{Fe} refers to S configuration at the planar chiral element.

Note: To maintain consistency in all of this work when assigning configuration at phosphorus we have given the Ugi amine (1-N,N-dimethylamino)ethylferrocenyl) fragment a priority of 1, the incoming lithium or Grignard nucleophile (in the above example lithioferrocene) a priority of 2 and the remaining group a priority of 3. This method will not always be consistent with the rigorous approach. These assignations and the proposed phosphorus configurations have been checked using single crystal x-ray crystallography.

Example 2

2,2' bis-[(S_P,R_C,S_{Fe})(1-N,N-Dimethylamino)ethylferrocenyl)phenylphosphino]-4-tolylether **L2**



L2

Using a similar procedure to that described above with the exception that a suspension of 2,2' dilithio-4-tolylether [prepared by known procedures from 2,2' dibromo-4-tolylether (1.78 g, 5.0 mmol) and 1.5 M t-BuLi solution in pentane (14.0 ml, 21.0 mmol) in Et_2O (20 ml) at –78 °C] was used as the linker reagent rather than 1,1' dilithioferrocene.

Yellow crystalline solid $[\alpha]_D$ = -105 ° (c=0.005 (g/ml), toluene); ^1H NMR ($CDCl_3$, 400.13 MHz): δ 1.23 (d, 6H), 1.72 (s, 12H); 2.28 (s, 6H); 4.11 (s, 10H); 4.12 (m, 2H overlapping); 4.28 (m, 2H); 4.31 (m, 4H); 4.35 (m, 2H, overlapping); 7.00-7.30 (m, 14H) ppm. ^{31}P NMR ($CDCl_3$, 162 MHz): δ –40.69 (br s) ppm.

Example 3

2,7-di-tert-butyl-4,5-bis-[(S_P,R_C,S_{Fe})(1-N,N-Dimethylamino)ethylferrocenyl)phenylphosphino]-9,9-dimethyl-9H-xanthene



L3

Using a similar procedure to that described above with the exception that a suspension of 2,7-di-tert-butyl-4,5-dilithio-9,9-dimethyl-9H-xanthene [prepared by known procedures from 2,7-di-tert-butyl-4,5-dibromo-9,9-dimethyl-9H-

xanthene and 1.5 M t-BuLi solution in pentane in Et_2O at –78 °C] was used as the linker reagent rather than 1,1' dilithioferrocene.

Orange/yellow crystalline solid; ^1H NMR ($CDCl_3$, 400.13 MHz): δ 1.12 (s, 18H); 1.13 (m, 6 H overlapping); 1.78 (s, 6H); 1.98 (s, 12H); 3.99 (m, 2H); 4.15 (s, 10H overlapping); 4.32 (m, 2H); 4.41 (m, 4H); 7.00-7.40 (m, 14H) ppm. ^{31}P NMR ($CDCl_3$, 162 MHz): δ –41.78 (br s) ppm. HRMS (10eV, ES+): Calcd for $C_{63}H_{75}Fe_2N_2OP_2$ $[M+H]^+$: 1049.4053; Found: 1049.4222



Scheme 1.0 Route for the synthesis of substrates of formula (VI)

Example 4

General hydrogenation screening method:

Into a 45 ml autoclave was placed ligand (3.25 x 10^{-3} mM) and the vessel placed under vacuum/Ar cycles. The vessel was then flushed with Argon. A degassed solution of $[(COD)_2Rh]BF_4$ in MeOH (5 ml of a 0.64 mM solution) was then added by syringe/needle and a rubber bung placed over the vessel to maintain an inert atmosphere. This mixture was stirred for 10 min to give a clear yellow solution. A degassed solution of starting material in MeOH was then added by syringe/needle while carefully attempting to maintain an inert atmosphere. The autoclave was then connected to a Parr 3000 multi-vessel reactor system and then placed under Ar (5 bar) and vented while stirring, this process was repeated 3 times. After the final vent the mixture was placed under H_2 (50 bar) and again vented carefully. The mixture was then placed under H_2 (50 bar), sealed and heated to the desired temperature for the required time. After this time the reaction mixture was cooled and the vessel vented. An aliquot of 0.5-1.0 ml was then taken for analysis.

Example 5

(S)-2-(3-(3-methoxypropoxy)-4-methoxybenzyl)-3-methylbutanoic acid



Into a 45 ml autoclave was placed *1,1' bis-[(R_P,S_C,R_{Fe})* **L1** (0.0063 g,0.0069 mmol), $[(COD)_2Rh]BF_4$ (0.0025 g, 0.0061 mmol) and (*E*)-2-(3-(3-methoxypropoxy)-4-methoxybenzylidene)-3-methylbutanoic acid (2 g, 6.49 mmol). The vessel was then placed under vacuum/Ar cycles. The vessel was then flushed with Argon and a rubber bung placed over the vessel to maintain an inert atmosphere. Degassed MeOH (10 ml) was then added by cannula taking care to maintain an inert atmosphere in the vessel. The vessel was then sealed and stirring commenced. The vessel was then placed under Ar (5 bar) and vented, this process was repeated three times. The autoclave was then placed under H_2 (50 bar) and again vented carefully. The mixture was then placed under H_2 (50 bar), sealed and heated to 40 °C for 12 h. After this time the reaction mixture was cooled and the vessel vented. An aliquot of 0.5-1.0 ml was then taken for analysis. Conversion >98%, e.e >98.5 % (major enantiomer second running peak).

^1H NMR ($CDCl_3$, 250.13 MHz): δ 1.01 (m, 6H), 1.95 (m, 1H); 2.05 (m, 2H); 2.45 (m, 1H); 2.78 (m, 2H); 3.35 (s, 3H), 3.55 (m, 2H); 3.83 (s, 3H); 4.10 (m, 2H); 6.65-6.80 (m, 3H).

HPLC method for e.e. determination of 2-(3-(3-methoxypropoxy)-4-methoxybenzyl)-3-methylbutanoic acid

Chiralpak-AD column (250 mm x 4.6 mm), 94 % Hexane, 3 % 2-methyl-2-propanol and 3 % t-amyl alcohol, flow: 1 ml/min, 230 nm. S-acid 13.15 min

(largest peak with bis-[(R_P,S_C,R_{Fe})] ***1***), R-acid 14.01 min, starting material 42.73 min.

HPLC method for e.e. determination of 2-(3-(3-methoxypropoxy)-4-methoxybenzyl)-3-methylbutanoic acid (methyl ester) - diazomethane derivatization

Into a 10 ml vial was placed a stirring bar and a 1ml aliquot of the crude hydrogenation reaction mixture. With vigorous stirring trimethylsilyl diazomethane in hexane (2 M) was added drop-wise into the reaction mixture and the good yellow colour of the diazomethane solution disappeared along with good gas evolution. This drop-wise process was continued until the reaction mixture became a yellow colour and gas evolution ceased. Neat acetic acid (15-30 µl, - Caution too much acetic acid and excessive gas evolution occurs) was then added upon which the mixture became very pale yellow. Approximately 1/3 of this mixture was then filtered through a small pad of wetted silica in a Pasteur pipette washing with a little hexane/IPA (80:20). The resulting solution was then analysed using HPLC: Chiralpak-AD column (250 mm x 4.6 mm), 95 % Hexane, 5 % i-Propyl alcohol, flow: 1 ml/min, 230 nm. Product enantiomers; 9-10 min, Starting material; 14-16 min.

Note: the order of elution of the enantiomers is reversed relative to analysis on the non-derivatized acids.

1,1' bis-[(S_P,R_C,S_{Fe})] **L1** yields *(R)-2-(3-(3-methoxypropoxy)-4-methoxybenzyl)-3-methylbutanoic acid*

1,1' bis-[(R_P,S_C,R_{Fe})] **L1** yields *(S)-2-(3-(3-methoxypropoxy)-4-methoxybenzyl)-3-methylbutanoic acid*



(E)-2-(3-(3-methoxypropoxy)-4-methoxybenzylidene)-3-methylbutanoic acid

Example 6

Table 1.0 Results of enantioselective hydrogenations on (E)-2-(3-(3-methoxy-propoxy)-4-methoxybenzylidene)-3-methylbutanoic acid with bis-[(S_P,R_C,S_{Fe})] **L1** at 50 bar H_2 pressure.

entry	s/c ratio	T (°C)	Substrate [M]	Conversion (%)	e.e.
1	500:1	40	0.16	>95	99.6[1]
2	500:1	50	0.16	>95	99.6[2]
3	500:1	65	0.16	>95	99.3[2]
4	1000:1	40	0.55	72	98.5[3]
5	2000:1	40	0.55	72	98.3[3]

1 Reactions carried out in MeOH for 20 h
2 Reactions carried out in MeOH for 5 h
3 Reactions carried out in MeOH for 14 h

Example 7

Table 2.0 Results of enantioselective hydrogenations on (E)-2-(3-(3-methoxy-propoxy)-4-methoxybenzylidene)-3-methylbutanoic acid with bis-[(S_P,R_C,S_{Fe})] **L1** at 50 bar H_2 pressure.

entry	s/c ratio	T (°C)	Substrate [M]	Solvent MeOH:1-BuOH	e.e.
1	1000:1	40	0.65	8.75:1	98.7
2	1000:1	50	0.65	8.75:1	98.2
3	1000:1	65	0.65	8.75:1	96.6

Example 8

Table 3.0 Results of enantioselective hydrogenations on (E)-2-(3-(3-methoxypropoxy)-4-methoxybenzylidene)-3-methylbutanoic acid with bis-[(S_P,R_C,S_{Fe})] **L1** at 50 bar H_2 pressure (using solid addition method*)

entry	Time (h)	T (°C)	Substrate [M]	s/c ratio	e.e.
1	4	50	0.55	1000:1	98.6
2	4	60	0.55	2000:1	98.4
3	4	60 for 1 h then 50	0.55	1000:1	98.2

Note: in all cases >98 % conversion was observed

* All solids (substrate, ligand and metal source) placed in vessel then solvent added

Example 9

Ligands containing flexible linker units have been found to be most preferable for the enantioselective hydrogenation of the acid substrates described.



L2

Table 4.0 Results of enantioselective hydrogenations on (E)-2-(3-(3-methoxypropoxy)-4-methoxybenzylidene)-3-methylbutanoic acid with ligands **L1-L3** at 50 bar H_2 pressure in MeOH.

entry	**Ligand**	T (°C)	Time (h)	S/C ratio	Conversion (%)	e.e. (%)
1	L1	40	12	1000:1	83	>99
2	L2	40	12	1000:1	52	90.8

Example 10

HPLC method for e.e. determination for (S)-2-ethoxy-3-(thiophen-2-yl)propanoic acid (as methyl ester)



After derivatization:

Chiralpak™-AD column (250 mm x 4.6 mm), 95 % Hexane, 2.5 % 2-methyl-2-propanol and 2.5 % t-amyl alcohol, flow: 1 ml/min, 236 nm. Enantiomers 5.44 and 5.81 min (largest peak with bis-[(S_P,R_C,S_{Fe})] ***1***).

Example 11

HPLC method for e.e. determination for (S)-3-(3-(benzyloxy)-4-methoxyphenyl)-2-ethoxypropanoic acid



Chiralpak™-AD column (250 mm x 4.6 mm), 93 % Hexane, 7 % i-Propyl alcohol, flow: 1.2 ml/min, 235 nm. Enantiomers 11.71 min, 13.33 min (largest peak with bis-[(R_P,S_C,R_{Fe})] ***1***), starting material 36.68 min.

Example 12

Table 5.0 Results of enantioselective hydrogenations on (*Z*)-[-(3-Benzyloxy-4-methoxyphenyl)]-2-ethoxyacrylic acid with bis-[(S_P,R_C,S_{Fe})] ***1*** at 48 bar H_2 pressure for 12 h.

entry	s/c ratio	T (°C)	Substrate [M]	e.e. (%)
1	2000:1	50	0.40	96.2
2	2000:1	50	0.83	93.4
3	250:1	55	0.25	97.1
4	500:1	55	0.5	97.6
5	1000:1	55	1.0	94.9
6	1500:1	55	1.5	90.9
7	1000:1	80	1	81.2

All reactions carried out in MeOH

All reactions achieved >98% conversion

Example 13

HPLC method for e.e. determination for (S)-2-ethoxy-3-(thiophen-3-yl)propanoic acid



Chiralpak-AD column (250 mm x 4.6 mm), 99 % Hexane, 1 % i-Propyl alcohol, flow: 0.7 ml/min, Integrated 235-239 nm. Enantiomers 9.71 min, 10.88 min (largest peak with bis-[(R_P,S_C,R_{Fe})] ***1***), starting material16.35 min.

Example 14

HPLC method for e.e. determination for (S)-2-ethoxy-3-(3-methoxyphenyl)propanoic acid (as methyl ester)



After derivatization:

Chiralpak-AD column (250 mm x 4.6 mm), 95 % Hexane, 2.5 % 2-methyl-2-propanol and 2.5 % t-amyl alcohol, flow: 1 ml/min, Integrated 280-290 nm. Enantiomers 7.49 and 10.00 min (largest peak with bis-[(S_P,R_C,S_{Fe})] ***1***).

Example 15

Table 6.0 Screening results of enantioselective hydrogenations on various (Z)-substituted 3-aryl-2-ethoxyacrylic acid substrates with bis-[(S_P,R_C,S_{Fe})] ***1*** at 50 bar H_2 pressure.

entry	s/c ratio	T (°C)	Substrate [M]	Substituted aryl	e.e. (%)
1	500:1	40	0.41	3-OMe	95.2
2	1000:1	40	0.82	3-OMe	94.6
3	500:1	35	0.50	4-CN	98.0
4	500:1	55	0.50	4-CN	96.5
5	500:1	50	0.41	2-thienyl	95.0
6	1000:1	55	0.41	3-thienyl	96.5

All reactions carried out in MeOH

CLAIMS

1. A metallocene-based phosphine or arsine ligand for use in enantioselective catalysis, the ligand having the Formula:



wherein:

M is a metal;
Z is P or As;
L is a linker;

R^1 is substituted branched-chain alkyl, substituted straight-chain alkyl, unsubstituted branched-chain alkyl, unsubstituted straight-chain alkyl, alkoxy, alkylamino, substituted cycloalkyl, unsubstituted cycloalkyl, substituted cycloalkoxy, unsubstituted cycloalkoxy, substituted cycloalkylamino, unsubstituted cycloalkylamino, substituted carbocyclic aryl, unsubstituted carbocyclic aryl, substituted carbocyclic aryloxy, unsubstituted carbocyclic aryloxy, substituted heteroaryl, unsubstituted heteroaryl, substituted heteroaryloxy, unsubstituted heteroaryloxy, substituted carbocyclic arylamino, unsubstituted carbocyclic arylamino, substituted heteroarylamino, or unsubstituted heteroarylamino, wherein the or each heteroatom is independently sulphur, nitrogen, or oxygen; and

X* is:





wherein R, R^2 and R^3 are independently substituted branched-chain alkyl, substituted straight-chain, alkyl unsubstituted branched-chain alkyl, unsubstituted straight-chain alkyl, substituted cycloalkyl, unsubstituted cycloalkyl, substituted carbocyclic aryl, unsubstituted carbocyclic aryl, substituted heteroaryl or unsubstituted heteroaryl, wherein the or each heteroatom is independently sulphur, nitrogen, or oxygen, and wherein when R^2 and R^3 are both attached to nitrogen they may be co-joined.

2. A ligand according to claim 1 wherein when R^2 and R^3 are both attached to nitrogen they form an optionally substituted hetero-ring.

3. A ligand according to claim 1 or claim 2 which exhibits chirality at Z.

4. A ligand according to claim 3 wherein the chiral configuration of the first Z substituent bound to L is the same as the chiral configuration of the second Z substituent bound to L.

5. A ligand according to any one of claims 1 to 4 wherein L is derived from a dianionic reactive species.

6. A ligand according to claim 5 wherein L is metallocenes, diphenyl ethers, xanthenes, 2,3-benzothiophene, 1,2-benzene, cyclic anhydrides or succinimides.

7. A ligand according to claim 6 wherein L is ferrocene.

8. The enantiomer of a ligand according to any one of claims 1 to 7.

9. The diastereomer of a ligand according to any one of claims 1 to 8.

10. A transition metal complex containing a transition metal coordinated to the ligand according to any one of claims 1 to 9.

11. A transition metal complex according to claim 10 wherein the transition metal is a Group VIb or a Group VIII metal.

12. A transition metal complex according to claim 11 wherein the metal is rhodium, ruthenium, iridium, palladium, platinum or nickel.

13. Use of a ligand according to any one of claims 1 to 9 in enantioselective catalysis.

14. Use of a transition metal complex according to any one of claims 10 to 12 in enantioselective catalysis.


X*
R1
Z
L
M
2

(I)


R
NR2R3
O
SH
R2
H
O
O
OR2
R2
O
N
R3
N
OR2

(II)


R3
N–N
OR2
R3
OR2
Me
N
Me
R2O
Ph
N